Abstract
Epidemiological modelling is a key method of pandemic management including that of SARS-CoV-2. New insights into epidemiologic mechanics and new data resources require continuous adaptions of modelling approaches. We here present a revised and considerably extended version of our previous SARS-CoV- 2 model implemented as input-output non-linear dynamical systems (IO-NLDS). We now include integration of age-dependent contact patterns, immune waning, and new data resources such as seropositivity studies, hospital dynamics, variant dynamics, non-pharmaceutical intervention measures and dynamics of the vaccination campaigns.
With this modelling framework, we explain the dynamics of several data resources for the complete pandemics in Germany as well as its 16 federal states. The latter also allows us to investigate the heterogeneity of model parameters in Germany for the first time. To achieve this goal, we extend our estimation approach by constraining variation of parameters among the federal states. This allows reliable estimation of a few thousand parameters using hundreds of thousands of data points.
Our approach can be generalized to other epidemic situations or even other areas of application, thus, supporting general pandemic preparedness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was funded by the German Federal Ministry of Education and Research (BMBF 031L0296A (PROGNOSIS) with respect to updating the epidemiologic model and BMBF 031L0299E (OptimAgent) with respect to estimating federal state heterogeneity).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used only the data located in public domain
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
